Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 3/20 | 0.42 |
| ▸ | XPNPEP2 | O43895 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20839141 | 1.00 | ALDH1A1 (0.45) | ALDH1A1GRM3MAPK1ACEXPNPEP2 | |
| SCHEMBL12430299 | 0.88 | ALDH1A1 (0.46) | ALDH1A1GRM3MAPK1ACEXPNPEP2 | |
| SCHEMBL22991239 | 0.85 | ALDH1A1 (0.44) | ALDH1A1GRM3MAPK1ACEXPNPEP2 | |
| SCHEMBL3397046 | 0.85 | ALDH1A1 (0.54) | ALDH1A1MAPK1KDM4EKMT2AHSD17B10 | |
| SCHEMBL21431189 | 0.84 | DPP4 (0.48) | ALDH1A1GRM3MAPK1ACEXPNPEP2 | |
| SCHEMBL3718155 | 0.81 | SMN1; SMN2 (0.46) | ALDH1A1MAPK1ACEXPNPEP2SMN1; SMN2 | |
| SCHEMBL22431751 | 0.79 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2KDM4ENPC1HPGD | |
| SCHEMBL28434432 | 0.79 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2KDM4ENPC1HPGD | |
| SCHEMBL28434429 | 0.79 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2KDM4ENPC1HPGD | |
| SCHEMBL6831699 | 0.78 | ALDH1A1 (0.51) | ALDH1A1GRM3MAPK1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684762-B1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2023-05-03 | — | — | EP | disclosed |
| EP-3941906-B1 | QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2023-05-03 | — | — | EP | disclosed |
| EP-3941906-A1 | QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | Lead Discovery Center GmbH (DE) | 2022-01-26 | — | — | EP | disclosed |
| US-11111238-B2 | Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2021-09-07 | — | — | US | disclosed |
| WO-2020188049-A1 | QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-09-24 | — | — | WO | disclosed |
| US-20200291011-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-09-17 | — | — | US | disclosed |
| EP-3684762-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | Lead Discovery Center GmbH (DE) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019057821-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111238-B2 | Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | POLRMT, UQCRC2, UQCRC1 | ALDH1A1 1261/4885GRM3 4660/4885MAPK1 3532/4885 |
| US-20200291011-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | POLRMT, UQCRC2, UQCRC1 | ALDH1A1 1261/4885GRM3 4660/4885MAPK1 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.